9,249 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Virtus Advisers LLC

Virtus Advisers LLC purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,249 shares of the biotechnology company’s stock, valued at approximately $754,000.

Several other institutional investors also recently modified their holdings of the stock. Vise Technologies Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $379,000. E Fund Management Co. Ltd. purchased a new position in Arrowhead Pharmaceuticals in the 2nd quarter worth $476,000. Myecfo LLC purchased a new position in Arrowhead Pharmaceuticals in the 2nd quarter worth $1,426,000. Citizens Financial Group Inc. RI bought a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at about $309,000. Finally, BlackRock Inc. purchased a new position in Arrowhead Pharmaceuticals in the 2nd quarter worth approximately $1,208,838,000. 62.61% of the stock is currently owned by institutional investors.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Adeoye Y. Olukotun sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. This trade represents a 5.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael S. Perry sold 11,600 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the sale, the director directly owned 111,459 shares of the company’s stock, valued at $9,730,370.70. This represents a 9.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.60% of the company’s stock.

Analysts Set New Price Targets

ARWR has been the subject of several recent analyst reports. HC Wainwright upped their price objective on shares of Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Chardan Capital raised their price objective on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Leerink Partners boosted their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research report on Wednesday, June 17th. Morgan Stanley increased their price objective on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Finally, B. Riley Financial raised their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.33.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock opened at $87.47 on Friday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $19.82 and a twelve month high of $95.49. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The company’s 50-day moving average price is $82.59 and its 200-day moving average price is $72.77. The company has a market cap of $12.32 billion, a PE ratio of -38.88 and a beta of 1.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.Arrowhead Pharmaceuticals’s revenue for the quarter was up 171.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.26) EPS. On average, equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.